Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
212 active trials3 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Clinical trials
555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03800953 | The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Sep 8, 2021 |
| clinicaltrials |
| NCT03387904 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04514835 | A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC | unknown | Phase 2 | 44 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04063683 | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04533490 | A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT04888403 | Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04984018 | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 73 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04880811 | Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification | unknown | Phase 2 | 43 | Peking UniversityOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03766178 | Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04275986 | Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma | unknown | Phase 2 | 56 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04866381 | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody | unknown | Phase 2 | 87 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT03585530 | Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 32 | Huai'an First People's HospitalOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04797507 | SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer | unknown | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 0 | Mar 15, 2021 | clinicaltrials |
| NCT04767295 | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 28 | Hunan Cancer HospitalOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT03377400 | Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer | unknown | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03987815 | Neoadjuvant Nivolumab for Operable Esophageal Carcinoma | unknown | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04644250 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 32 | Wei RenOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04602013 | Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 53 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04481100 | CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer | unknown | Phase 2 | 38 | Hangzhou Cancer HospitalOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT04437212 | Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02123381 | Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 45 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT03913182 | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT04229849 | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 164 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 18, 2020 | clinicaltrials |
| NCT04006041 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer | unknown | Phase 2 | 44 | Jianhua FuOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT04115618 | SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT04054518 | Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma(DESC) | unknown | Phase 2 | 22 | Tiago BiachiOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03185988 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | unknown | Phase 2 | 100 | Shen LinOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT03940976 | Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03927495 | KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT02812641 | Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC | unknown | Phase 2 | 50 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 | clinicaltrials |
| NCT03857763 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 0 | Feb 28, 2019 | clinicaltrials |
| NCT03833466 | Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)(ECMTPneo) | unknown | Phase 2 | 15 | Peking UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02353936 | A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Feb 11, 2019 | clinicaltrials |
| NCT03817567 | Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 50 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03817658 | A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC | unknown | Phase 2 | 725 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT03732508 | SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | unknown | Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT03585673 | Docetaxel-polymeric Micelles(PM) and Oxaliplatin for Esophageal Carcinoma(DOSE) | unknown | Phase 2 | 38 | Sung Yong OhOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT02384811 | Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Sep 7, 2017 | clinicaltrials |
| NCT03224221 | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | unknown | Phase 2 | 189 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT02913066 | S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 88 | Mianyang Central HospitalOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00816634 | Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma(XP versus XT) | unknown | Phase 2 | 94 | Samsung Medical CenterOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT02665702 | Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | unknown | Phase 2 | 76 | Fudan UniversityOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT02325986 | Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer | unknown | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT02586753 | Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus | unknown | Phase 2 | 2 | Mianyang Central HospitalOTHER | 0 | Oct 26, 2015 | clinicaltrials |
| NCT02188615 | Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer(NACRFMIE) | unknown | Phase 2 | 120 | Chengchu ZhuOTHER | 1 | Jul 11, 2014 | clinicaltrials |
| NCT02016274 | Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer | unknown | Phase 2 | 70 | Shen LinOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT02016287 | Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer | unknown | Phase 2 | 50 | Shen LinOTHER | 1 | Dec 19, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 16, 2021source: clinicaltrials